

SONFIELD & SONFIELD

A Professional Corporation

LEON SONFIELD (1865-1934)
GEORGE M. SONFIELD (1899-1967)
ROBERT L. SONFIELD (1893-1972)

ATTORNEYS AT LAW
2500 WILCREST DRIVE, 3RD FLOOR
HOUSTON, TEXAS 77042-2754
WWW.SONFIELD.COM

ROBERT L. SONFIELD, JR.
Managing Director
robert@sonfield.com

FRANKLIN D. ROOSEVELT, JR. (1914-1988)

Telecopier (713) 877-1547

Jennifer Abney
Legal Assistant
Jennifer@sonfield.com

Telephone (713) 877-8333

January 24, 2022

OTC Markets Group Inc.
304 Hudson Street, 2nd Floor
New York, New York 10013

Re: VirExit Technologies Inc. (OTC: PVDG) (the “Issuer” or the “Company”)

Ladies and Gentlemen:

Our firm, as a U.S. resident, serves as special disclosure and corporate securities counsel to VirExit Technologies Inc. (the “Issuer”) and has been asked to render this opinion with respect to the adequacy of the current information contained in the Issuer’s Annual Report for the fiscal years ended August 31, 2020 and 2019, as well as the Notes to the Financial Statements, posted on the OTC Disclosure & News Service on the 6th day of January 2022, Officer/Director Disclosure Statement for the fiscal year ended August 31, 2020, posted on the OTC Disclosure & News Service on the 7th day of January 2022, Annual Report for the fiscal years ended August 31, 2021 and 2020, as well as the Notes to the Financial Statements, posted on the OTC Disclosure & News Service on the 12th day of January 2022, Officer/Director Disclosure Statement for the fiscal year ended August 31, 2021, posted on the OTC Disclosure & News Service on the 12th day of January 2022, Quarterly report for the month ended November 30, 2021, as well as Notes to the Financial Statements, posted on the OTC Disclosure & News Service on the 14th day of January 2022, as compiled, unaudited financial statements, and Officer/Director Disclosure Statement for the fiscal quarter ended November 30, 2021, posted on the OTC Disclosure & News Service on the 14th day of January 2022, (collectively, the “Disclosures”). We have been asked to express our opinion as to the adequacy of the Disclosures within the meaning of Rule 144(c)(2) promulgated under the Securities Act of 1933 (“Act”).

OTC Markets Group, Inc. (“OTC Markets”) may rely on this opinion in determining whether the Issuer has made adequate current information publicly available within the meaning of Rule 144(c)(2) of the Act and, more specifically, paragraphs (a)(5)(i) to (xiv), inclusive, and paragraph (a)(5)(xvi) of Rule 15c2-11.

We have examined such corporate records and other documents and such questions of law and regulations as we have deemed necessary or appropriate for purposes of rendering this opinion. As to matters of fact, we have made such inquiries of the Issuer’s officers as we deemed necessary to render this opinion, and we believe that such sources were reliable.

The person responsible for the preparation of the compiled, unaudited financial statements is L. Bruce Jolliff, a licensed Certified Public Accountant in the State of Washington.

SONFIELD & SONFIELD

OTC Markets Group, Inc.

January 24, 2022

Page 2

The Issuer's transfer agent is Globex Transfer, LLC ("Transfer Agent"). The Transfer Agent is registered with the SEC as such under the Securities Exchange Act ("Exchange Act"). By examination of the compiled, unaudited financial statements for the fiscal years ended August 31, 2021, 2020 and 2019 as well as quarterly report for the month ended November 30, 2021, we have determined the number of outstanding shares of the Issuer to be as set forth in the Disclosures with information provided by the Transfer Agent and L. Bruce Jolliff, Chief Financial Officer of the Issuer.

The undersigned attorney has (a) personally met with management and a majority of the directors of the Issuer, including James C. Katzaroff and L. Bruce Jolliff, (b) reviewed the Disclosure Statement, Supplemental Information, and the OTC Pink Basic Disclosure Report as of August 31, 2021 and November 30, 2021 posted for the Issuer on the OTC Disclosure & News Service, and (c) discussed the Disclosure Statement with a majority of the directors of the Issuer.

The Issuer's counsel is not currently under investigation, litigation or the subject of an injunction, restraining or similar order issued by any court, state or federal, or by any federal or state regulatory authority related to any violation of federal or state securities laws.

The Issuer's counsel is not currently, and has not in the past five years, been the subject of an investigation, hearing, or proceeding by the SEC, the U.S. Commodity Futures Trading Commission (CFTC), the Financial Industry Regulatory Authority (FINRA), or any other federal, state, or foreign regulatory agency.

The Issuer has provided written representation that, based on personal knowledge, review of public filings and review of the Issuer's business and financial records, the Issuer has never been a shell company as defined by Rule 405 and Rule 144(i)(1)(i) of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934.

To our knowledge, after inquiry of management and a majority of the directors of the Issuer, the Issuer, no holder of five percent (5%) or more of its securities, nor the Issuer's counsel is currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.

As a result of the foregoing, we are of the opinion that:

1. The Disclosures constitute "adequate current public information" concerning the Issuer's securities and the Issuer within the meaning of Rule 144(c)(2).
2. The Disclosures are "available" within the meaning of Rule 144(c)(2).
3. The Disclosures include all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Issuer's securities under Rule 15c2-11 under the Exchange Act.
4. The Disclosures comply as to form with OTC Markets Group's Pink Basic Disclosure Guidelines for Providing Adequate Current Disclosure Statement.
5. The Disclosures have been posted through the OTC Disclosure & News Service.

The undersigned attorney is admitted to practice law in the State of Texas, and this opinion is limited solely to the laws of the United States of America. The undersigned attorney is permitted to

SONFIELD & SONFIELD

OTC Markets Group, Inc.

January 24, 2022

Page 3

practice before the Securities and Exchange Commission ("SEC") and has not been prohibited from such practice or has not been in the past five years, suspended or barred from practicing in any state or jurisdiction, and has not been charged in a civil or criminal case.

The undersigned attorney does not beneficially own any shares of the Issuer's securities and has no agreement to receive shares of the Issuer's stock in payment for services in the future.

The opinions set forth herein are expressed as of the date hereof and remain valid so long as the documents, instruments, records and certificates I have examined and relied upon as noted above, are unchanged and the assumptions I have made, as noted above, are valid.

This opinion is rendered solely to OTC Markets and no person other than OTC Markets is entitled to rely upon it. However, we grant OTC Markets full and complete permission and rights to publish this opinion through the OTC Disclosure & News Service for viewing by the public and regulators.

Yours very truly,

A handwritten signature in black ink, appearing to read "Robert L. Sonfield, Jr.", with a stylized flourish at the end.

Robert L. Sonfield, Jr.
Managing Director